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Hematopoietic stem cells (HSCs) represent one of the first recognized somatic stem cell types. As such,
nearly 200 genes have been examined for roles in HSC function in knockout mice. In this review, we compile
the majority of these reports to provide a broad overview of the functional modules revealed by these genetic
analyses and highlight some key regulatory pathways involved, including cell cycle control, Tgf-b signaling,
Pten/Akt signaling, Wnt signaling, and cytokine signaling. Finally, we propose recommendations for charac-
terization of HSC function in knockoutmice to facilitate cross-study comparisons that would generate amore
cohesive picture of HSC biology.In the field of design, the minimalist movement stripped down
buildings and objects to their most basic features, a sentiment
that architect Ludwig Mies van der Rohe summarized in his
motto ‘‘less is more.’’ By depleting HSCs of specific genes,
knockout studies transpose the minimalist approach into
research biology, providing insights into the essential core of
genetic features that is indispensable for a well-functioning
hematopoietic system.
Introduction
The mammalian blood system is comprised of an array of cell
types, including erythrocytes (red blood cells), myeloid cells
(granulocytes and monocytes/macrophages), megakaryocytes
and platelets, lymphocytes (B and T cells), natural killer cells
(NKs), dendritic cells (DCs), and mast cells. As diverse as
these cells are, they all originate from hematopoietic stem cells
(HSCs), which are a limited pool of immature progenitors residing
in the bone marrow (Figure 1). At the very top of the cellular hier-
archy lies a reservoir of long-term HSCs (LT-HSCs). LT-HSCs
guarantee a continuous supply of blood cells throughout an
individual’s lifetime due to their potential to self-renew (give
rise to identical daughter cells) and differentiate. Downstream
of LT-HSCs are pools of stem and progenitor cells with
decreasing self-renewal potential: the short-term HSCs (ST-
HSCs) and multipotent progenitors (MPPs), which retain full
differentiation capacity, and the lineage-restricted progenitors:
common lymphoid progenitors (CLPs), common myeloid
progenitors (CMPs), megakaryocyte/erythrocyte progenitors
(MEPs), and granulocyte/macrophage progenitors (GMPs).
These downstream progenitors are the real workhorses of the
hematopoietic system, as they divide rapidly and generate
a large number of differentiated progeny. In order to guarantee
blood homeostasis, the system is tightly regulated but also
highly resilient and capable of modulating the production of
specific progeny in response to bleeding, infections or environ-
mental insults. This resilience is the result of two opposing
forces—one sustaining HSC dormancy, or quiescence, which302 Cell Stem Cell 11, September 7, 2012 ª2012 Elsevier Inc.is critical to maintain a reservoir of stem cells, and the other, acti-
vating proliferation and differentiation. Disrupting this balance
can have a variety of pathologic consequences, such as bone
marrow failure or hematologic malignancy. Thus, it is important
to understand the forces that regulate hematopoietic stem and
progenitor cell function.
Over the past 20 years, a number of genes that influence
HSC function have been uncovered by analyses of knockout
(KO) mice, lending insight into some of the key regulators of
HSC self-renewal and differentiation. Our goal here is to collate
most of these reported KO phenotypes in order to synthesize
what the phenotypes collectively tell us about the genetic and
functional modules critical to HSC function. First, we review
the general phenotypic classes and commonly linked observa-
tions, which broadly reveals the types of functional modules crit-
ical to HSCs. Second, we take a pathway-specific approach,
examining how the phenotypes of KO mice within particular
well-studied pathways illuminate the relative importance of
each pathway and help to predict additional genes that may be
worth investigating for their role in regulating HSCs. Finally, we
suggest a set of analyses that could be considered part of a
standardized assessment to determine whether a particular
gene plays a role in HSC function.
Overview of the Major Phenotypic Categories
We scanned the literature to identify the majority of instances
in which the HSC function of a KO mouse had been studied.
We identified around 150 individual KO mice that had been at
least partially characterized for an HSC phenotype (Table S1
available online). Several of these genes were studied by
multiple laboratories, and a number of reports describe concom-
itant disruption of additional genes (double- or triple-KO mice),
resulting in over 200 papers with a rigorous analysis of HSC
function after gene disruption. We examined these papers to
determine what kind of KO model was used (e.g., null or condi-
tional), and classified the type and severity of the phenotype.
In our final analysis, we only included studies in which bone
Self-
renewal
Differentiation
Quiescent
LT-HSC
MPP
GMLPCMP
GMPMEP
Erythrocyte
Platelets
Granulocyte
Macrophage Dendritic cell NK cell B Lymphocyte T Lymphocyte
Mature
cells
Lineage
Committed
Progenitors
Oligopotent
Progenitors
Multipotent
Progenitors
Stem Cell
Compartment
ECM
Thymus
ST-HSC
Activated
LT-HSC
Osteoclast
Osteoblast
CAR cells Nestin
MSC
+
Schwann
cell
Nerve fiber BM microenvironment
Stromal
cell
External
Macroenvironment
Infective agents
 
Bleeding
 
Chemotherapy
Genotoxic stress
CLP
Bone
Marrow
Figure 1. Overview of the Hematopoietic Hierarchy
At the top of the mammalian blood system is a restricted pool of multipotent long-term HSCs (LT-HSCs), capable of sustaining a continuous supply of blood cells
throughout an individual’s lifetime. Long-term maintenance of hematopoiesis depends on HSC quiescence and, at the same time, on their capability to rapidly
respond to proliferative stimuli generated by the BM niche or the external macroenvironment. Downstream of LT-HSCs are pools of stem and progenitor cells with
increasingly diminished self-renewal potential: short-term HSCs (ST-HSCs), multipotent progenitors (MPPs), and lineage-restricted progenitors, such as
common lymphoid progenitors (CLPs), common myeloid progenitors (CMPs), granulocyte/macrophage/lymphocyte progenitors (GMLPs), megakaryocyte/
erythrocyte progenitors (MEPs), and granulocyte/macrophage progenitors (GMPs). By proliferating rapidly, these progenitors generate a large pool of mature
cells that eventually exit the BM and enter the peripheral blood. Notably, some details of this hierarchy are still in flux as evidenced by much discussion in the
literature not covered here.
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Figure 2. Overview of Hematopoietic Phenotypes
(A and B) Data from Table S1 were sorted according to phenotype, duplicate
phenotypes of the same gene were removed, and the categories were
apportioned as indicated. A few genes are represented in multiple categories
(e.g., increased engraftment and cancer—such as Cbl KO, or enhanced
engraftment after the primary transplant followed by a total loss of function
after a secondary transplant—such as Hif1a). (A) Summary of phenotypes
affecting HSCs as per Table S1. Phenotypes were ascertained from our
interpretation of data in the cited papers. Increased function: Enhanced
peripheral blood (PB) production from KO cells after HSC or BM trans-
plantation. (B) Summary of different degrees of hematopoietic defects found in
KO mice, as per Table S1. Categories were arbitrarily defined as follows.
Severe defect: less than 20% of PB production (relative to normal) in both
myeloid and lymphoid lineages after deletion or transplantation of KO HSCs or
bone marrow; moderate defect: reduction in generation of PB to between
20%–70% of normal; mild defect: reduction in PB to between 70%–100% of
normal.After serial: normal hematopoiesis after primary transplant, but defects
in PB production emerge after secondary or tertiary transplant.
(C) Examples of KO phenotypes relative to generalized expression patterns.
Breadth of expression gleaned from Unigene EST profiles, Goodell lab data
(http://www.bcm.edu/labs/goodell) or the Immunological Genome Project
(http://www.immgen.org). See Table S1 for details. Readers can add to
the database and obtain updated versions of Table S1 at http://www.
bonemarrowhsc.com/hsc-phen/.
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assess the capacity of the KO HSCs to regenerate blood and
bone marrow (the most rigorous test of stem cell activity). There
was large variation in the methodologies used to assess stem
cell function, but we attempted to classify reported phenotypes
through a single lens, judging their severity based on the degree
of peripheral blood regeneration after bone marrow (or HSC)
transplant (percent contribution of donor-derived cells in recipi-
ents based on our interpretation of data presented in the papers)
(Figure 2) (please see Table S1 for description of our classifica-
tion scheme). This means that the collection of these studies in
this review share one common methodology—transplantation304 Cell Stem Cell 11, September 7, 2012 ª2012 Elsevier Inc.analysis, which we believe to be the standard of quantifying
HSCs in vivo. While some studies inadvertently may have not
been included, having this relatively large number of KO mice
to examine allows us to make some broad observations based
on the frequency of various phenotypes (with the caveat that
mild or negligible phenotypes are likely under-reported due to
publishing constraints).
First, we find that over two-thirds (116/152) of the analyses
reported some degree of defect in peripheral blood regenera-
tion when HSCs or bone marrow cells from KO mice were
transplanted in order to test HSC function (Figure 2A). Of these,
severe and moderate engraftment defects each comprised
about two-fifths of analyzed KO mice; a small proportion of
defects were only uncovered after serial transplantation
(Figure 2B, also likely underreported).
Severe Phenotypes
The genes that when ablated resulted in a severe phenotype
(defined arbitrarily as less than 20% of blood production from
KO cells within 2–3 weeks of gene deletion or after bone marrow
or HSC transplantation) fell into a range of functional classes and
gene expression patterns (Figure 2C). Ablation of some genes
that are highly restricted in their expression to HSCs, such as
HoxA9, led to nearly immediate demise of the HSCs (Lawrence
et al., 2005). These mutants are of high interest due to their
potential to reveal genetic modules that are uniquely important
for HSCs (and early progenitors where their expression is often
shared). Severe phenotypes are also observed with some
broadly expressed genes, which often have central functions
for many rapidly dividing cells, such as Lkb1 and Atm (Gan
et al., 2010; Gurumurthy et al., 2010; Ito et al., 2004; Nakada
et al., 2010). Some KOsmay show little impact on baseline blood
homeostasis, but exhibit a severe defect after stress or trans-
plantation (e.g., Irgm1) (Feng et al., 2008), underscoring the value
of transplantation to assay HSC function.
While severe phenotypes have shaped our understanding of
the processes essential to HSCs, their analysis and interpreta-
tion can present special challenges. First, if the KO HSCs are
incapable of repopulating the bone marrow, it can be difficult
to discern whether this is due to lack of differentiation capacity,
engraftment ability, or simply due to lack of HSC survival. It is
also not possible on the basis of the initial transplantation data
to assert that such a gene impacts HSC ‘‘self-renewal’’; if loss
of the gene prevents initial engraftment, the ability to regenerate
HSCs also cannot be assayed. Similarly, if loss of a broadly ex-
pressed gene results in a severe phenotype, it can be difficult to
distinguish between a unique impact on HSC function and an
impact on some or all of the downstream progeny (e.g., MPP,
CLP, CMP, or differentiated cells). In vitro assays may in some
cases provide some insights, but development of specific Cre-
deleter strains may eventually be required to dissect more finely
cell-type specific roles.
Moderate Phenotypes
Within KOs that result in a moderate phenotype (20%–70% of
blood production from KO cells relative to WT), we also see
that the targeted genes display a wide range of gene expression
patterns. Some highly HSC-restricted genes such as Evi1 and
cMpl result in moderate phenotypes, although in some cases,
different KO alleles of these key regulators have distinct effects
(Zhang et al., 2011). Moderate phenotypes are also observed
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poietic regulators, e.g., Pu.1, which is required for development
of multiple lineages (Iwasaki et al., 2005). Some genes may have
moderate KO phenotypes due to genetic redundancy; for
example, Lyl1 and Scl1 have moderate and mild effects respec-
tively when deleted in the adult (Capron et al., 2006; Hall et al.,
2003; Mikkola et al., 2003) but the double KO has a severe
phenotype due to rapid demise of dKO cells (Souroullas et al.,
2009).
Mild Phenotypes and Effects Only Seen upon Serial
Transplantation
A relatively mild phenotype (70%–100% of blood production
from KO cells relative to WT), particularly ones that can only be
seen after serial transplantation, can be initially disappointing
to investigators, but can also lend critical insights into HSC func-
tions such as ‘‘self-renewal.’’ If HSCs can differentiate and
engraft in their niche normally in the initial host, but are defective
in generating additional functioning HSCs after further transplan-
tation, the role of a gene may be very specific for mechanisms of
self-renewal. For example, deletion of cdkn1a (p21), cd81, prnp,
and Tnfrsf1 (p55) resulted in decreased peripheral regeneration
only after secondary or tertiary transplantation (Cheng et al.,
2000b; Lin et al., 2011; Rebel et al., 1999; Zhang et al., 2006a),
demonstrating defective regeneration of otherwise seemingly
normal HSCs.
Ablation of some genesmay result inmild phenotypes if we are
unable to adequately assay the aspect of the HSC lifestyle
controlled by that gene. Along these lines, it is interesting that
Hif1a KO has a relatively mild impact on HSC function, with
a transplantation defect apparent only upon secondary trans-
plantation (after augmented activity in the primary recipients)
(Takubo et al., 2010). Although considered a ‘‘universal’’ regu-
lator, Hif1a may have HSC-specific roles due to the specialized
hypoxic microenvironment in which HSCs reside. Similarly,
Necdin is another highly HSC-specific regulator controlled by
p53 (Liu et al., 2009b) that only exhibits a mild KO phenotype
of delayed regeneration (e.g., Ndn) (Kubota et al., 2009). Necdin
may be redundant with another gene(s), or may control other
aspects of the HSC function not tested by conventional assays.
Cell Extrinsic Effect
A small portion of KO mice exhibited a cell extrinsic defect that
affected stem cell function (e.g., Dicer and Opn) (Raaijmakers
et al., 2010; Stier et al., 2005). Generally, this is determined by
transplanting WT stem cells into a KO recipient, and observing
the impact on stem cell engraftment and blood regeneration.
We expect this category to be overall underexplored, because
most mutants are simply not tested in this manner unless there
is a reason to expect a phenotype in the supporting niche. Never-
theless, such experiments can reveal key functional elements of
the niche and would be worth performing in a wider variety of
mutants. It is notable that although we think of the HSC niche
as the cellular nonhematopoietic elements (e.g., stromal, osteo-
blasts, and endothelial cells) that support and instruct the HSCs,
there is also feedback to stem cells from other hematopoietic
cells. Such feedback would include environmental effects
caused by aberrant function of downstream progeny of the
mutant transplanted HSC. A prime example is the critical role
of thrombopoietin, which is released by platelets, and directly
regulates HSC homeostasis (de Graaf et al., 2010). Likewise,loss of Interleukin10 (Il10) resulted in HSC defects because
of the imbalance of cytokine production in progeny cells that
ultimately affected HSCs (Kang et al., 2007). Similarly, loss of
CD48, which is expressed on most HSC progeny but excluded
from dormant HSCs, resulted in HSC defects due to deregulated
cytokine signaling (Boles et al., 2011).
Increased HSC Activity and Malignancy Development
A moderate proportion (24/150) of KO mice were reported to
have an increase in HSC function (Figure 2A). This enhanced
function is observed as a greater proportion of peripheral blood
generated from KO HSCs compared to WT control HSCs after
HSC or bone marrow transplantation. We believe genes with
this relatively rare KO phenotype are particularly instructive
because their products constrain stem cell number or function
in some manner. There were multiple functional categories
described in this class. Loss of two different proteins involved
in ubiquitin-mediated protein degradation resulted in an increase
in HSC activity: Cbl and Itch (Rathinam et al., 2008, 2011); their
targets, not yet described, may be involved in promoting HSC
differentiation or proliferation. Transcription factors whose
deletion led to increased HSC function include Hif1a and Egr1
(Min et al., 2008; Takubo et al., 2010). The KO phenotypes of
these genes are distinguished by serial transplantation, as the
dominance of these ‘‘super-HSCs’’ may fade after secondary
(e.g., Hif1a KO) or tertiary (e.g., Egr1 KO) transplantation. Dele-
tion of the DNA methyltransferase 3a (Dnmt3a) also led to an
apparent increase in HSC activity measured by blood produc-
tion; however, this belied what was actually an alteration of the
balance between self-renewal and differentiation that became
exposed upon serial transplantation and HSC quantification
(Challen et al., 2012).
We might expect that loss of genes that restrain HSCs would
inevitably lead to malignancy. Indeed this is the case in some
examples, such as loss of Tet2 (Ko et al., 2011; Moran-Crusio
et al., 2011; Quivoron et al., 2011) and combined loss of Cbl
and Cbl-b (Naramura et al., 2010) (hence, a few genes are
included in multiple categories in Figure 2). It is possible that
other mutants that expand HSCs would also ultimately lead to
transformation if observed over a sufficient period of time.
In general, mutations that increase HSC function (without
leading to malignancy development) are of special interest as
some of these gene products could be manipulated to expand
HSCs ex vivo, a long-sought goal that would have implications
for cellular therapies and bone marrow transplantation. How-
ever, increased HSC function is a challenging phenotype to
dissect. Increased HSC progeny can be a result of increased
HSC number in the KO (perhaps of developmental origin)
with normal HSC function. Alternatively, the phenotype could
reflect higher differentiation capacity (faster generation of down-
stream cells from normal HSC numbers), or even increased self-
renewal. All of these possibilities are informative, but as more
members of this phenotypic class are uncovered, it will be
important to distinguish the mechanisms, and of course, identify
any mutants that truly expand ‘‘normal’’ HSCs, from those that
simultaneously promote malignant transformation.
Developmental versus Adult Phenotypes
Primitive HSCs are first formed in the embryonic yolk sac, and
definitive HSCs later in the aorta-gonad-mesonephros (AGM)
region as well as in the placenta (Gekas et al., 2005) fromwhenceCell Stem Cell 11, September 7, 2012 ª2012 Elsevier Inc. 305
Cell Stem Cell
Reviewthey migrate to the fetal liver. In the fetal liver, HSCs undergo
tremendous expansion before migrating around the time of birth
to the bone marrow, where the majority reside throughout life.
The genes required in HSC emergence (e.g., Scl and Runx1)
are not covered here. However, the fetal liver (FL) harbors
HSCs that have developmental potential highly similar to
adult-derived HSCs, and their functions can be tested by trans-
plantation into adult recipients. Importantly, their physiology
is quite distinct, as they are rapidly expanding in contrast to
the quiescent adult HSCs; therefore, we may expect (and
observe) different genetic requirements for these distinct stages.
However, only a handful of genes have been tested for their
roles in both FL and adult hematopoiesis [this often requires
both a null allele (for FL analysis) and a conditional allele (for adult
analysis)]. Sox17 is the paradigmatic example of a gene required
for FL-HSC function that is dispensable in the adult (Kim et al.,
2007). In contrast, the CDK inhibitor p57 (Cdkn1c) had minimal
impact when the null allele was tested at the FL hematopoiesis
stage (Zou et al., 2011), whereas deletion in the adult led to
a moderate HSC defect (Matsumoto et al., 2011). Importantly,
secondary transplantation from mice originally transplanted
with FL-derived HSCs showed that the p57-deficient HSCs did
indeed display a defect once they had assumed their adult
(quiescent) status (Zou et al., 2011). This finding underscores
the unique physiology of the fetal versus adult states, and
demonstrates the value of a secondary transplantation. In the
future, we expect additional genes will be revealed to play
a more important role at one or another period in development;
these will generate insights into the regulatory modules that
are important for the common (self-renewal and differentiation)
and distinct (proliferation status and developmental potential)
properties of HSCs at different developmental stages.
A Pathway and Functional View
Cell Cycle Control
Under homeostatic conditions, adult HSCs that reside in the
bone marrow niche are largely quiescent (in the G0 phase of
the cell cycle), in a state of relative dormancy that is believed
to be critical for their biological role (Wilson et al., 2008). Because
passage through the cell cycle offers the HSC an opportunity to
change its state, committing to differentiation or returning to
self-renewal, the role of cell cycle regulators in HSC function
have been thoroughly dissected (Figure 3), sometimes leading
to unexpected results.
The cell cycle is regulated by cyclins that, after binding cyclin-
dependent kinases (Cdk), phosphorylate target proteins in-
volved in proliferation. The complex formed by D-cyclins and
Cdk4/6 controls progression through the G1 phase and, likely,
HSC exit from quiescence: if we examine genetic deficiency of
regulators of the G1 phase, we see that mice lacking a single
D-cyclin or Cdk present with minimal hematopoietic phenotype,
suggesting functional redundancy within the system. However,
D-type cyclins are collectively required for HSC function, as
triple D1/D2/D3/ KO mice exhibit decreased absolute
numbers of HSCs and progenitors with impaired repopulating
ability (Kozar et al., 2004). Within the Cdk family, loss of Cdk2
and Cdk6 does not affect adult hematopoiesis in both single
and double mutants, suggesting that their function is dispens-
able in HSCs (Berthet et al., 2007; Malumbres et al., 2004).306 Cell Stem Cell 11, September 7, 2012 ª2012 Elsevier Inc.However, Cdk4/6/ double mutants also present with defects
in FL hematopoiesis similar to those described in triple D-cyclin
knockout mice, highlighting the pivotal role of the cyclin D/Cdk4
complex in HSC cell cycle (Malumbres et al., 2004).
Among the downstream targets of D-cyclins/Cdk4/6
complexes are members of the retinoblastoma (Rb) tumor
suppressor gene family, such as Rb, p107, and p130. These
proteins have long been known to critically control cell cycle
dynamics, and deletion of their corresponding genes was ex-
pected to severely destabilize hematopoiesis. Surprisingly, no
major defects appeared in Rb-deficient HSCs and cell cycle
dysregulation became evident only under stress (Daria et al.,
2008). Likewise, loss of p130 produced no hematopoietic
phenotypes and only a mild hyperplasia emerged in p107 null
mice (Cobrinik et al., 1996; LeCouter et al., 1998). Only when
all the three genes were simultaneously deleted did the com-
partment of early hematopoietic progenitors display a significant
increase in proliferation and a hematopoiesis reconstitution
defect after transplantation (Viatour et al., 2008), indicating that
Rb, p107, and p130 collectively regulate HSC cell cycle.
The Cdk inhibitors, that inactivate Cdk4-Cdk6/D-cyclin heter-
odimers in the face of antiproliferative signals, exhibit distinct
phenotypes after ablation. Loss of p18 (Cdkn2c) results in
more potent HSCs that exhibit superior engraftment in multiple
rounds of transplantation (Yuan et al., 2004). Interestingly, p16
(Cdkn2a) loss results in an expanded functional HSC pool only
in old mice, potentially linking p16 in particular with the hemato-
poietic decline that emerges with age (Sherr and Roberts, 1999;
Stepanova and Sorrentino, 2005; Yuan et al., 2004). These
observations also correspond with phenotypes resulting from
ablation of genes whose products regulate these regulators,
such as Bmi1 (Park et al., 2003).
CDK inhibitors functioning in late G1, such as p21, p27, and
p57, also have been examined. Although p21 (Cdkn1a) was
initially regarded as a key regulator of the entry of HSCs into
the cell cycle (Cheng et al., 2000b), recent investigation revealed
that its role is more restricted to conditions of cellular stress and
DNA damage, as observed after exposure to radiation (van Os
et al., 2007). Cdkn1b (p27) deletion increases the pool of short-
term progenitors and their repopulating power, suggesting that
p27 primarily plays an antiproliferative role in progenitor cells,
rather than primitive HSCs (Cheng et al., 2000a). In contrast,
Cdkn1c (p57) expression is highly enriched in HSCs, relative to
their progeny, where it plays a key role (Matsumoto et al.,
2011; Zou et al., 2011). Conditional ablation of Cdkn1c (p57)
leads to a significant decrease of adult hematopoietic pro-
genitors and HSCs and a loss of HSC quiescence. Notably,
p27 (but not p21) compensates for p57 loss, as indicated by
Cdkn1b/Cdkn1c double knockouts (Zou et al., 2011).
p53 has long been known as a master regulator of cellular
responses to genotoxic stress and DNA damage. Interestingly,
recent studies have demonstrated that p53 is highly expressed
in the HSC compartment and actively takes part in processes
promoting their quiescence under steady-state conditions (Liu
et al., 2009a). Ablation of Trp53 (p53) resulted in an increase in
long-term progenitors, although their quiescence appeared
decreased.
Although cell-cycle pathways are among the most studied
features in HSC knockout reports, several genes and molecular
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(A) Cell cycle regulators play a pivotal role in HSCmaintenance by tuning the balance between quiescence and self-renewal. Gene names are enclosed in boxes,
colored based on the degree of hematopoietic defect evident from KO studies.
(B) Summary of KO phenotypes related to genes involved in cell cycle regulation. All indicated phenotypes are derived from in vivo transplantation experiments.
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maintenance of quiescence or activation of self-renewal. The
results emerging from this research area will help enlighten
how the molecular alterations found in leukemic stem cells
contribute to aberrant proliferation.
Perturbation of the Cell Cycle Status
The majority of adult-derived HSCs reside in a quiescent state,
so it has been generally accepted that this is an important
property of HSCs. If so, we would predict that mutants that
promote HSC proliferation would lead to lower HSC function,
and those that increase quiescence would lead to higher HSC
activity. Broadly, we can see that disruption of other regulators
that lead to perturbation of the cell cycle can have a dramatic
impact on HSC function (Table S2). Many mutants that result insustained hyperproliferation of HSC are associated with a severe
hematopoietic defect (e.g., Adar1, Gfi1, and Irgm1 (Feng et al.,
2008; Hartner et al., 2009; Hock et al., 2004)). There are likely
a number of mechanisms behind this, including HSC division
events that are associated with rapid differentiation, or intrinsic
control of the cell cycle.
Nonetheless, there are a range of alterations to HSC cell cycle
kinetics that are associated with different levels of engraftment
defects, and a few genetic models even show that increased
HSC proliferation does not necessarily lead to HSC exhaustion,
suggesting that the link between maintenance of stem cell
functions and cell-cycle progression is complex. For instance,
inactivation of Cdkn2c (p18) leads to the expansion of both
stem and progenitor cells without HSC exhaustion or loss ofCell Stem Cell 11, September 7, 2012 ª2012 Elsevier Inc. 307
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HSCs that retain increased stem cell potential even through
secondary transplantation (Yuan et al., 2004). Similar findings
were reported in specific c-Myb mutants: despite the increased
cell-cycle activity, mutant HSCs displayed a remarkable
increase in their repopulation potential, up to tertiary transplanta-
tion (Sandberg et al., 2005). A number of other models share this
behavior (Table S1), in which stem cell functions are preserved—
or, in some cases, even enhanced—despite the accelerated
HSC proliferation.
Overall, these paradoxical phenotypes associated with in-
creased proliferation—severe HSC defects in some cases
versus increased HSC function in others—clearly indicate our
poor understanding of the link between HSC proliferation and
self-renewal. While quiescence, or dormancy, is a property inex-
tricably linked to the HSC, cell division is obligate for self-renewal
and provides an opportunity for differentiation, as the nucleus
is remodeled during mitosis. An intriguing explanation of the
conundrum is that some genes not only affect the entry of
HSCs into the cell cycle, but also determine the susceptibility
of HSCs to the effects of other genes or environmental cues.
Such genetic factors may either promote HSC regeneration or
drive differentiation, with the ultimate outcome reflecting the
balance between the forces driving self-renewal and differen-
tiation. Understanding this puzzle will illuminate the molecular
machinery that presides over the maintenance of the HSC
compartment, possibly lend insight into malignancies, and may
lead to the development of strategies to expand HSCs without
differentiation ex vivo, which remains a highly desirable research
and therapeutic goal.
TGF-b Pathway
TGF-b is a multifunctional protein, involved in a wide variety of
processes, including immune responses, tumor development
and angiogenesis. In vitro colony formation studies had long
hinted at a key role for TGF-b in HSC regulation, and the avail-
ability of KO mice finally allowed its importance to be analyzed
in vivo. These studies have revealed complex requirements,
suggesting that TGF-b activity varies depending on the cell
type and stage of differentiation.
In mammals, three TGF-b isoforms have been described
(TGF-b1, -b2, and -b3), which bind to two different membrane
receptors—known as TbRI and TbRII—and activate specific
Smads, organized in two separate nodes (Smad2/3 and Smad1/
5/8). The separate branches of TGF-b eventually converge to
activate Smad4, which translocates into the nucleus and
modulates the transcription of target genes. Although knockout
mice lacking TGF-b receptors (either TbRI or TbRII) die early
during embryonic development, hematopoiesis remains unaf-
fected (Larsson et al., 2001), which is also confirmed through
analyses of conditional TbRI mutant mice (Larsson et al.,
2003). Of note, TbRIII appears to modulate R1/RII activity, but
has not yet been tested for the control of HSCs (Stenvers
et al., 2003).
Smad5 is a major mediator of intracellular signaling activated
by bone morphogenetic proteins (which also belong to the
TGF-b family) and was expected to produce a significant impair-
ment in HSCs once deleted. However, conditional Smad5/
HSCs were capable of long-term multilineage reconstitution
(Singbrant et al., 2006), suggesting that Smad5 may be redun-308 Cell Stem Cell 11, September 7, 2012 ª2012 Elsevier Inc.dant with other Smads participating in the same branch. In
contrast, deletion of Smad4 resulted in a moderate self-renewal
defect (Karlsson et al., 2007). Together, these data suggest
redundant activation of convergent signaling pathways down-
stream of TGFb.
Among TGF-b knockouts, mice lacking TGF-b1 or TGF-b3
have not been documented to exhibit hematopoietic defects
whereas only the deletion of Tgfb2 affected HSCs. Tgfb2+/
BM cells display a moderate decrease in their repopulating
ability, while Tgfb2/ FL cells display a visible defect only
following serial transplantations (Langer et al., 2004). These find-
ings suggest that TGF-b2 may act as a positive regulator of HSC
functions in vivo, perhaps also dependent on developmental
stage (e.g., FL versus adult HSCs). Of note, niche-secreted
TGF-b was recently shown to regulate dormancy of HSCs in
the bone marrow (Yamazaki et al., 2011).
Additional information on the role of TGF-b in hematopoiesis
derives from knockout studies of genes that merge into the
same signaling cascade. The product of the gene Pbx1 (a
DNA-binding cofactor of several Hox proteins) has been shown
to play a critical role in the establishment and long-term mainte-
nance of murine hematopoiesis (Ficara et al., 2008). A remark-
able number of genes regulated by Pbx1 take part in the
TGF-b signaling pathway, making Pbx1 a potential trait d’union
between TGF-bmolecules andHSC functions.Pbx1/ embryos
are incapable of multilineage hematopoiesis and display a pro-
gressive loss of quiescent HSCs, ultimately leading to severe
repopulation defects. In addition, Pbx1/ HSCs are less
responsive to TGF-b stimulation and fail to upregulate the
expression of several down-stream mediators, including
Smad7 and Cdkn1c (p57) (DiMartino et al., 2001; Ficara et al.,
2008).
Overall, the role of TGF-b signaling in HSCs appears to be
more complex than initially suggested by in vitro studies.
Knockout models have contributed to the dissection of TGF-b
signaling in the two separate branches, which differently affect
HSC function depending on the developmental context.
However, other pathway members may need to be investigated
before the role of TGF-b in HSCs can be fully appreciated.
Alternative pathways may also involve Endoglin (CD105), an
ancillary TGF-b receptor and also an HSC marker (Chen et al.,
2002a; Yamashita et al., 1994). Endoglinmayprovide a substitute
path for TGF-b signaling, possibly accounting for the lack of
a stem cell defect in Tgfbr1 conditional knockouts. In addition,
Endoglin has been shown to enhance signaling through Smad2
(Santibanez et al., 2007), which participates with Smad3 in
a signaling node leading to the translocation of Smad4 into the
nucleus. Due to the defects documented in Smad4/ HSCs
(but not seen in Smad5/ animals), both Smad2 and Smad3
knockouts are anticipated to harbor defective HSCs. In support
of this view, recent work has shown that both Smad2 and Smad3
are highly phosphorylated in quiescent long-term HSCs (but not
in proliferative HSCs (Yamazaki et al., 2009)), suggesting a
fundamental role for the Smad2/3 node in HSC function. Overall,
the mild phenotypes of mutants in multiple nodes of the TGF-b
pathway imply eithermarked regulatory redundancywithin a crit-
ically important pathway, or an inconsequential role. In the
future, the concurrent deletion of multiple downstream media-
tors of the TGF-b signaling (such as Smad1/Smad5 double
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the role of TGF-b in HSCs.
Pten/Akt Pathway
Akt signaling, activated by growth factors, triggers a number of
cell responses including proliferation, survival, growth, modula-
tion of metabolic functions, and resistance to stress. Phospha-
tase and Tensin homolog (Pten) is a negative regulator of the
phosphatidylinositol-3-OH kinase (PIK3)-Akt pathway. Mecha-
nistically, Pten acts as a negative regulator of this pathway and
inhibits Akt activation by dephosphorylating PIP3 (phosphatidy-
linositol 3,4,5 trisphosphate). Mutations in genes in the Pten/Akt
signaling pathway have been shown to influence both HSC
number and quiescence.
The Pten tumor suppressor gene is often mutated in tumors,
and several investigations highlight the role of Pten/Akt pathway
in both normal hematopoiesis and leukemia. Mice with a condi-
tional loss of Pten in the hematopoietic system present with
a significant depletion of the stem cell pool (Table 1, Table 2,
and Table S1); mutant mice have decreased numbers of LT-
HSCs, while the ST-HSCs remain unaffected. Strikingly, loss of
Pten has been linked to leukemogenesis; mutant mice develop
a myeloproliferative disorder that eventually evolves into acute
leukemia (Guo et al., 2008; Yilmaz et al., 2006; Zhang et al.,
2006b).
Genes downstream of Pten have also been examined. Loss
of either Akt1 or Akt2 has only subtle consequences on hemato-
poiesis. Conversely, HSC function in Akt1//Akt2/ double
mutants is significantly impaired, as displayed by competitive
transplants (Juntilla et al., 2010), suggesting a functional overlap
between the two members of the family. Several studies also
focused on Forkhead O (FoxO) proteins, a family of transcription
factors involved in cell proliferation, differentiation, apoptosis,
and resistance to stress agents. FoxO proteins are negatively
regulated by the PI3K/Akt pathway and, similar to Pten inactiva-
tion, Akt activation results in FoxO phosphorylation and inhibi-
tion. As a consequence, the hematopoietic phenotype of
FoxO-deficient mice is strikingly similar to that of Pten-deficient
mice, with the exception that FoxO knockouts do not develop
leukemia (Tothova et al., 2007). The conditional deletion of
all three FoxO genes (FoxO1, FoxO3a, and FoxO4) has been
reported to reduce LT-HSCs numbers and their ability for
long-term multilineage reconstitution (Tothova et al., 2007).
Incidentally, the deletion of FoxO3a alone resulted in loss of
hematopoietic reconstitution ability, and this defect in hemato-
poietic engraftment manifested in secondary and tertiary
BM-transplants, supporting a regulatory role for FoxOs in HSC
self-renewal (Miyamoto et al., 2007).
Besides controlling the size of the HSC pool, FoxO proteins
promote HSC quiescence as well. Several proteins involved
in cell cycle regulation (including Rb/p130, Cyclin D2, Cyclin
G2, p21, and p27) represent transcriptional targets of FoxOs.
The concomitant loss of FoxO 1, 3, and 4 was shown to increase
the number of actively cycling LSK HSCs (Tothova et al., 2007).
Likewise, HSCs from FoxO3a/ mice proliferate more and
present decreased levels of both p27 and p57 (Miyamoto
et al., 2007). HSC functional defects found in FoxO mutant
mice are likely the consequence of a more intense cycling
activity that drives HSCs out of quiescence and progressively
depletes the stem cell compartment.The Pten/Akt/FoxO pathway offers a rich vein for other poten-
tial studies. By looking at the Pten/Akt/FoxO pathway, we
may make additional predictions on how perturbations of this
pathway will affect the stem cell pool. For example, removing
inhibitors of Akt activation is expected to decrease FoxO tran-
scription, which will likely lead to an increase in HSC proliferation
and, possibly, to the premature exhaustion of the stem cell pool.
An additional avenue would be to explore the roles of particular
targets of the pathway by the generation of animals with multiple
null alleles. For instance, Akt can activate the NF-kB pathway
through the activation of the inhibitory kB kinase IKK. On the
other hand, Akt-driven phosphorylation has been shown to
play a role in regulating apoptosis through the activation of
BAD. A double mutant lacking Bad and Ikk could be used to
separate the effects of Akt through BAD or IKK-dependent cell
survival pathways from its effects through FoxO transcription.
Such studies would likely provide further mechanistic insights
into this pathway in HSC biology.
The Wnt Pathway
Wnt ligands are a family of secreted glycoproteins that interact
with membrane-associated receptors to activate signaling
cascades. Wnt-dependent pathways (classically distinguished
in canonical and noncanonical branches) are involved in diverse
processes such as embryonic development, cell differentiation,
proliferation and polarity. Of note, many Wnt proteins are ex-
pressed in blood cells, and aberrant activation of Wnt-depen-
dent signaling has been reported in several hematologic malig-
nancies, suggesting a pivotal role of Wnt-signaling in blood cell
production. However, over the past decade, investigation of
the role of the Wnt signaling pathway in hematopoiesis has
lead to controversial results. Varied experimental approaches
can partly account for the difficulty in reaching a consensus.
However, recent reports suggest that different variables such
as developmental stage, Wnt protein dosage, and microenviron-
mental factors contribute to tuning the impact of Wnt signaling,
making the role of Wnts in HSCs difficult to generalize.
The so-called canonical Wnt signaling cascade, in which
b-catenin is stabilized and translocated into the nucleus, is
arguably the best studied. However, Ctnnb1 (b-catenin) KO
studies have generated results that are difficult to reconcile:
conditional Mx1-Cre-mediated inactivation of Ctnnb1 in adult
animals resulted in normal HSC repopulation and self-renewal
(Cobas et al., 2004). However, Vav-Cre-mediated deletion of
Ctnnb1 showed decreased long-term repopulation efficiency
of b-catenin-deficient HSCs (Zhao et al., 2007). Because Vav-
Cre exerts its effect during fetal hematopoiesis, the apparent
discrepancy may indicate a developmental requirement for
b-catenin. b-catenin may be less critical in adult HSCs, or com-
pensated by other proteins. Indeed, the continued influence of
b-catenin in adult HSCs is supported by overexpression of
constitutively active b-catenin, which caused severe disruptions
in HSC function and led to a differentiation block (Kirstetter et al.,
2006; Scheller et al., 2006).
Wnt3a, a ligand in theWnt signaling pathway, has been shown
to play a role in FL HSC function, as Wnt3a null mice exhibit
a significant reduction in FL HSC numbers, the function of which
is also severely impaired in serial transplantation (Luis et al.,
2009). Similar findings derive from Sox17 knockout mice. The
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Table 1. Summary of Phenotype of KO Mice (Excerpt of Online Table S1)
Gene
Type of
Mouse FL
Engraftment Ability in Transplantation Assays Cell
Extr Canc Comments PMIDSev Mod Mild After Serial Norm Incr
Gfi1 KO + KO HSCs cannot compete
with WT HSCs in
2-month-old chimeric mice
15457180
Sox17 KO + + + decreased fetal HSCs;
no impact in adults
17655922
Lkb1 cKO
(Mx1-Cre)
+ HSCs profoundly depleted
18 days after deletion;
pancytopenia
21124450;
21124456;
21124451
Irgm KO + hyper interferon signaling;
increased HSC proliferation
18371424
CD48 KO + + + increased HSC quiescence;
dysregulated cytokine
signaling; lymphomas
21576698
Hoxa9 KO + + FL: defective engraftment
of Hoxa9/ FL HSCs
17761289;
16091451
PU.1 cKO
(Mx1-Cre)
+ + decrease in FL HSC; block in
myelomonocytic differentiation
15914556
IL10 KO + + IL10 expressed in endosteal
osteoblasts; hypocellular Pre-TP
17464085
Smad4 cKO
(Mx1-Cre)
+ decreased repopulation;
Pre-TP: reduction in RBC
17353364
Hif1alpha cKO
(Mx1-Cre)
+ + increased engraftment after
1TP, and almost total loss
after 2TP; increased cycling
20804974
CD81 KO + severe defect only after 2TP;
CD81 promotes quiescence
after TP
21931533
Opn
(Spp1)
KO + + + increased engraftment after KO
BM TP, lost by 2TP; host effect
15928197
Egr1 KO + + increased engraftment
and circulating HSCs;
defect after 3TP
18397757
Necdin KO + slightly reduced stress recovery 19770359
Dicer cKO
(Osx-Cre)
+ + + increased HSC proliferation
and apoptosis; MDS
and leukemia; host effect
20305640
Gfi1b cKO
(Mx1-Cre)
+ + increased engraftment;
increased ROS in HSCs
20826720
Cebpa cKO
(Mx1-Cre)
+ + + increased engraftment in 1TP and
2TP; myeloid diff. block in BM
15589173
Cbl KO + + increased HSC number
and repopulating ability;
myeloproliferative disease
18413713
Tet2 KO, cKO
(Mx1- and
Vav-Cre)
+ + increased progenitors;
development of CMML-like
disease; het. phenotype
21723200;
21873190;
21723201
Trp53 KO + 20%–50% incr after competitive TP;
increased HSC number
12829028
All indicated phenotypes are derived from in vivo transplantation experiments. KO, knockout; cKO, conditional KO; TP, transplant; 1TP, primary TP;
2TP, secondary TP; 3TP, tertiary TP; FL, hematopoietic defect seen at the fetal liver development stage; Sev, Severe defect: less than 20% multi-
lineage peripheral blood (PB) production fromKOcells after bonemarrow or HSC transplantation;Mod,moderate defect: reduction in generation of PB
to between 20%–70% of normal; Mild, mild defect: reduction in PB to between 70%–100% of normal. After Serial, defect observed only after serial
transplantation (normal hematopoiesis in 1TP). Incr, Increased function: KO mice that showed enhanced PB production after HSC or BM transplan-
tation. Cell Extr, cell extrinsic effect generally is shown by demonstrating an impact on PB production from WT HSCs after transplantation into KO
recipients. Canc, cancer development in KO or transplanted mice. PMID, PubMed ID number.
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Table 2. Summary of KO Phenotypes Related to Genes Involved in TGF-b and AKT/PTEN Pathways
Gene Type of Mouse
Initial
Defect
Engraftment Ability in Transplantation Analysis
Altered
Proliferation PMIDSev Mod Mild
After
Serial Nml Incr
Cells
Tested
Tgf-b Pathway
Pbx1 KO + + FL - 11468159
Pbx1 cKO (Mx1-Cre
and Tie2-Cre)
+ + BM + 18462698
Tgfb2 Het - + BM + 14707111
Smad4 cKO (Mx1-Cre) + + BM NA 17353364
Tgfb2 KO - + FL + 14707111
Tgfbr1 KO - + BM NC 12842983
Smad5 cKO (Mx1-Cre) - + BM NC 16896158
Pten/Akt Pathway
FoxO3a KO - + BM NC 18371339
AKT1/AKT2 dKO + + FL - 20354168
FoxO1/FoxO3/FoxO4 triple cKO
(Mx1-Cre)
- + BM + 17254970
Pten cKO (Mx1-Cre) + + BM + 16633340
Akt1 KO - + BM NA 20354168
Akt2 KO - + BM NA 20354168
All indicated phenotypes are derived from in vivo transplantation experiments. KO, knockout; cKO, conditional KO; Initial Defect: defective hemato-
poiesis evident before transplantation. Sev, Severe defect (as in Table 1); Mod, moderate defect; Mild, mild defect; After Serial, defect observed
only after serial transplantation. Nml, normal; Incr, Increased function. Cells Tested: FL, fetal liver; BM, bone marrow. Altered proliferation: NC,
no change; – indicates decreased proliferation, + indicates increased proliferation; NA, not analyzed. PMID, PubMed ID number.
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deletion of Sox17 resulted in a striking decrease in the FL-
derived HSCs, but conditional adult loss of Sox17 had minimal
impact (Kim et al., 2007). These data illustrate the importance
of inhibition of Wnt signaling during development and support
its distinct role in the adult.
Other inhibitors of the Wnt canonical pathway have provided
further insights. The product of the tumor suppressor gene
Apc (Adenomatous polyposis coli) negatively regulates the
Wnt/b-catenin signaling pathway. Conditional loss of Apc dras-
tically increases HSC cycling and ultimately leads to severe
defects in multilineage hematopoiesis (Qian et al., 2008). The
high levels of b-catenin found in Apc mutant cells bolster the
idea that abnormal activation of Wnt signaling is detrimental to
HSC function. Along these lines, differences in Wnt dosages
and activation levels of its pathway may be a factor in the
discrepancies previously observed by different investigators.
By combining different Apc conditional knockouts each permit-
ting different levels of Wnt signaling, Luis et al. recently created
five different levels of Wnt signaling in vivo (Luis et al., 2011).
Different levels of Wnt signaling appear to affect the balance
of HSC self-renewal versus differentiation. Mild levels of Wnt-
pathway activation contribute to HSC maintenance and result
in increased hematopoietic reconstitution. In contrast, abnormal
activation of the Wnt pathway hinders HSC self-renewal and
differentiation (Figure 4).
In addition to the intrinsic modulation of HSC functions, Wnt-
signaling in the hematopoietic niche is also crucial. Recent
studies have demonstrated stroma-mediated Wnt/b-catenin
effects that may eventually resolve some of the controversiesraised by previous investigations. Transgenic mice overexpress-
ing the Wnt inhibitor Dickkopf1 (Dkk1) in the osteoblastic lineage
display increased HSC proliferation and decreased regeneration
after transplantation (Fleming et al., 2008). Similarly, the en-
forced expression of the Wnt inhibitory factor 1 (Wif1) in osteo-
blasts produced loss of HSC quiescence and decreased
self-renewal ability (Schaniel et al., 2011). Secreted Frizzled-
related proteins (sFRPs) can also antagonize Wnt signaling
by directly binding Wnt ligands and preventing interaction
with their cognate receptors. Although Sfrp1 deletion has no
intrinsic consequences on the stem cell compartment, loss of
Sfrp1 in BM stromal cells leads to severe defects in HSC main-
tenance (Renstro¨m et al., 2009). The hematopoietic phenotypes
described here validate a requirement for canonical Wnt
signaling in the BM niche and highlight its function in containing
proliferation and maintaining HSC quiescence (Fleming et al.,
2008).
As compared to the canonical pathway, the role of non-
canonical Wnt signaling in HSCs is not as well defined and
therefore offers an opportunity for further research. KO of two
downstream targets of the noncanonical pathway, the small
Rho GTPase Rac1 and Rac2 resulted in defective fetal-liver
and adult hematopoiesis (Cancelas et al., 2005; Ghiaur et al.,
2008; Jansen et al., 2005). However, these genes have broad
roles in cell migration, and thus their phenotype may reflect
features other than Wnt signaling. Recently, noncanonical Wnt
signaling mediated by Frizzled (Fz8) was shown to antagonize
canonical Wnt signaling, contributing to quiescence of HSCs
through suppression of the NFAT-IFNg pathway (Sugimura
et al., 2012).Cell Stem Cell 11, September 7, 2012 ª2012 Elsevier Inc. 311
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Figure 4. Wnt Signaling in HSCs
(A) Maintenance of normal HSC function requires a tightly regulated Wnt dosage. While a decrease in Wnt signaling leads to loss of HSC quiescence and
self-renewal, mild increases in Wnt pathway activation contribute to HSC maintenance and result in enhanced hematopoietic reconstitution. However—much
as its inhibition—the excessive activation of Wnt pathway hinders HSC differentiation, leading to the loss of hematopoietic functions. Both positive and
negative regulators contribute to maintaining Wnt-signaling activation within physiological ranges: these include both intrinsic (cell-autonomous) and
extrinsic (microenvironmental) factors (the latter indicated in italics in the figure). Gene names are enclosed in colored boxes, based on the degree of
hematopoietic defect emerged from KO studies.
(B) Summary of KO phenotypes related to genes involved in Wnt signaling. All indicated phenotypes are derived from in vivo transplantation experiments.
KO: knockout; cKO: conditional KO; Defect after serial transplant: normal hematopoiesis after primary transplant, but defects emerge after secondary
or tertiary transplant; Increased function: KO mice that showed enhanced PB production after HSC or BM transplantation; PMID: PubMed ID number;
PD: Perinatal Death, NA: Not Analyzed, NC: No Change, BM: Bone Marrow, FL: Fetal Liver; x proliferation phenotypes in hematopoietic progenitors (not always
homogeneous HSCs).
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regulator of HSCs (and several other types of somatic stem
cells), its inherent complexity is far from being fully resolved.
More details are expected to emerge from knockout studies of
downstream Wnt-signaling effectors, such as Tcf3 and Tcf4,
which have already been shown to be critical in skin stem cells
(Nguyen et al., 2006). In addition, the role of the disheveled genes
(scaffolding proteins involved in both canonical and noncanoni-
cal signaling) in HSCs has yet to be examined. Finally, while
both canonical and noncanonical pathways need to be better312 Cell Stem Cell 11, September 7, 2012 ª2012 Elsevier Inc.elucidated for their role in HSCs, the greatest advances will lie
in discovering how the two branches of Wnt signaling are func-
tionally intertwined.
Cytokine Signaling in the Stem Cell Niche
Since the 1960s, the hematopoietic organs such as bonemarrow
and spleen have been known to be sources of soluble factors
that can stimulate differentiation of progenitor cells; these cyto-
kines and chemokines are natural candidates for regulating
HSCs. Niche factors that contribute to HSC maintenance are
more extensively summarized in a recent review (Mercier et al.,
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exogenous addition in in vitro culture or overexpression in vivo,
only a handful have been investigated by gene disruption for their
role in stem cell regulation.
Steel factor, also known as SCF or cKit ligand, was one of the
earliest soluble factors found to significantly affect HSC function.
Scf-deficient animals do not maintain long-term repopulating
activity (McCarthy et al., 1977). Thrombopoietin (TPO) has
been reported to promote HSC proliferation in combination
with SCF or IL3 (Sitnicka et al., 1996); and disruption of the
TPO receptor cMPL appeared to lead to a cell autonomous
defect in HSC engraftment (Kimura et al., 1998). Indeed, throm-
bopoietin (Thpo/) knockout mice have a 150-fold reduction in
HSC number (Qian et al., 2007). Similarly, angiopoietin-1 (Ang-1)
signaling through the receptor Tie2 is required for adult hemato-
poiesis (Puri andBernstein, 2003; Takakura et al., 1998) andHSC
quiescence and reconstitution ability is severely impaired in the
absence of Tie2/Ang-1 (Arai et al., 2004). By contrast, effects
of mutations in the TGFb pathway are relatively mild, perhaps
because of redundancy in the system (see section on TGFb
above). Finally, bone marrow of mice in which the receptor for
G-CSF, Csf3r, was ablated gave rise to a decreased number of
hematopoietic colonies compared to their WT counterparts,
suggesting a smaller hematopoietic progenitor pool (Liu et al.,
1996). Thus, a wide variety of soluble growth cytokines have
been implicated in the maintenance of the HSC population.
Use of knockout mice as recipients in bone marrow transplant
experiments is particularly informative to address the environ-
mental role of such secreted factors.
Perhaps unsurprisingly given the close interaction between
the hematologic and immune systems, a number of inflamma-
tory cytokines have also been found to influence HSC biology.
Mice mutant for the chemokine Cxcl12 show defects in
HSC homing to the bone marrow during the fetal liver to
bonemarrow transition in late gestation (Rebel et al., 2002); simi-
larly, mice lacking the Cxcl12 receptor Cxcr4 are hyper-
proliferative (Nie et al., 2008), and disruption of Cxcr4 signaling
leads to HSC mobilization (Christopher et al., 2009). Inter-
leukin-10 silencing has been shown to decrease HSC ability
to repopulate recipients (Kang et al., 2007). Likewise, trans-
plantation of IL-2 knockout HSCs results in decreased engraft-
ment (Chen et al., 2002b), suggesting that IL-2—typically
thought of as a T cell cytokine—plays a role in HSCmaintenance
as well.
Recently, work on Type 1 and Type II interferons (Ifns) has illu-
minated their central role in controlling HSCs, as they can drive
dormant stem cells into an active and proliferative state by acting
directly on the stem cells rather than by altering their niche
(Baldridge et al., 2010; Essers et al., 2009). Furthermore, loss
of negative regulators of Ifn signaling, including Interferon regu-
latory factor 2 (Irf2), Adar1, and Irgm1 (Feng et al., 2008; Hartner
et al., 2009; King et al., 2011; Sato et al., 2009) all lead to rapid
loss of HSC function through hyperproliferation in the absence
of tightly regulated Ifn signaling. It is likely that Ifn-stimulated
HSC proliferation leads to HSC deficits due to differentiation-
associated HSC proliferation. Regulation of HSCs by these
classic immune-system modulators may contribute to coordina-
tion of the entire immune response during infectious stress (King
and Goodell, 2011).The Ifn response has also been used extensively to generate
conditional KO mice: Mx1-cre (Ku¨hn et al., 1995), the most
commonly used Cre-deleter strain in HSC research, is inducible
due to its Ifn responsiveness. This has raised the possibility that
the pro-proliferative effects of Ifn induction may also impact
HSCs during conditional KO, an effect that must be taken into
account for data interpretation. Tamoxifen-inducible Cre dele-
tion (Hayashi andMcMahon, 2002)may circumvent this concern,
but thus far, has not proven to be as efficient in the hematopoi-
etic system. It would be useful to develop additional inducible
lineage-restricted Cre-deleter strains in order to ascertain
HSC-specific effects that are independent of Ifn and other cyto-
kine signaling.
Conclusions and Future Perspectives
The well-defined hematopoietic stem and progenitor cell
hierarchy, as well as its tractability as an experimental system,
has led to an impressive collection of studies that have probed
the impact of gene ablation on HSC function. The studies
encompassed in this review provide a framework in which to
consider the key functional modules of HSCs, and to consider
the major questions that still need illumination.
Collectively, these studies underscore the view that the unique
lifestyle of adult HSCs, characterized by periods of dormancy
followed by activation and return to quiescence, represents
a fine balance that is critical for long-term stem cell viability.
There is a relatively narrow window of tolerance within which
the cell cycle activity can be perturbed, either directly or indi-
rectly, while maintaining essentially normal or improved HSC
function. This is substantiated by the number of KOs in which
the cell cycle activity is perturbed with concomitant changes in
HSC function. However, we still do not understand the mecha-
nistic link between HSC cycling and (the general) loss of long-
term activity: does rapid HSC division normally favor symmetric
differentiation? In this context, the highly proliferative state of FL-
derived HSCs without compromising long-term HSC function is
particularly noteworthy; insights into the regulatory modes that
permit this distinction, implied by the different FL versus adult
phenotypes of some of the mutants collected here, could have
implications for ex vivo expansion of HSCs, as well as cancer.
Similarly, the role of genes that normally restrain HSC number
or function, the behavior of these KOs with regard to HSC
cycling, and the implications of these genes for malignancy
development warrants further study.
Broadly, these studies reinforce the notion that key pathways
such as Wnt and TGF-b -signaling strongly influence HSC cell
fate. The inability to generalize the specific roles of these
pathways in terms of an absolute requirement of specific HSC
functions probably reflects context-dependence (i.e., fetal
versus adult requirements) of the specific pathways, as well as
gaps in the analysis of specific pathway members. The roles
of these and other pathways can be further refined with new
mutants, combinations of mutants, and rigorous analyses of
stem cell function.
We also observe from this collection that the HSC ‘‘niche’’
could be much more broadly considered, capturing the larger
stem cell ‘‘environment’’ that includes cellular and noncellular
elements such as soluble growth factors and extracellular
matrix. Considering that we have little insight into howCell Stem Cell 11, September 7, 2012 ª2012 Elsevier Inc. 313
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Figure 5. Overview of Recommended Steps for Determining
whether a Gene Has an Impact on HSC Function
See Table S3 for details.
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Reviewappropriate HSC numbers are maintained despite their wide but
sparse dispersion through the vast bone marrow, understanding
such long-range feedback mechanisms that may work at an
organismal scale is important. This would promote the develop-
ment of a more holistic view of the way in which HSCs are
regulated in the context of normal and disease physiology.
What can we do to bring this analysis from a list of interesting
mutants to a sophisticated understanding of the mechanisms,
including all their subtleties, that regulate HSC function? We
expect that at any given time, there are extrinsic forces pushing
HSCs to differentiate, as well as others restraining them in the
niche. Elucidation of how these opposing signals are integrated
and interpreted by the HSC is needed.
Importantly, in order to better integrate our understanding of
these different mutants, we need to facilitate cross comparison
of emerging studies. After reviewing the 200 papers we cover
here, the challenge of comparing studies using widely differing
methodologies was starkly evident. Here, we suggest a set of
experiments to test whether a particular gene plays a role in
HSCs, not all of which need to be applied in every situation
(Figure 5, Table S3). The gold standard assay is testing the
function of the mutant HSCs by bone marrow or stem cell
transplantation, but ancillary studies will assist interpretation
(also see Purton and Scadden, 2007 for a comprehensive review
of some of these assays). Also, the increasing availability of
high-throughput sequencing may allow molecular signatures
of stem cell states to be defined by gene expression conse-
quences and/or transcription factor binding behavior after
gene perturbations; if performed in a standardized manner,
such data when accumulated might be comparable from lab
to lab, and thus enable relationships between different genetic
modules of HSCs to be inferred.
Finally, we think it will be important in the long run to distin-
guish between genes and functions that are critical to many/all
cells that have the potential to rapidly divide (e.g., DNA repair
genes and metabolic regulators), and those that have particular314 Cell Stem Cell 11, September 7, 2012 ª2012 Elsevier Inc.functions for HSCs. Some of this is inferred by HSC-specific
gene expression patterns (e.g., Nurr1; Sirin et al., 2010), but in
other cases, there may be HSC-specific post-transcriptional
regulatory mechanisms, such as protein modifications, micro-
RNA regulation, or substrate availability, that are not immediately
obvious.
Ultimately, the next big leap forward in our understanding will
derive from in vivo assessments of how graded changes in
signaling pathways affect HSC function, i.e., via combinatorial
and real-time assessments of gene expression using new
technologies like RNA seq. As we identify individual players,
we need to begin to understand how they work together in a
dynamic physiologic setting. This new level of understanding
will lead to improved application of gene-specific therapeutics
and the development ofmore integrative approaches to regener-
ative medicine.
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